Study investigates the role of endothelin (ET) re ceptors in mediating early changes in cerebral blood flow-as measured by laser Doppler flowmetry (CBFLDF)-during ex perimental pneumococcal meningitis. Meningitis was induced with heat-killed pneumococci and confirmed by a significant increase in CBFLDF (baseline 100%; 225.3 ± 21.8% after 6 hours; mean ± SD), intracranial pressure (ICP), brain water content, and white blood cell count in the CSF. Intravenous administration of the selective endothelin B (ET B ) receptor antagonist BQ-788 immediately before pneumococcal chal lenge (but not 4 hours afterward) significantly attenuated these pathophysiologic alterations (e.g., CBFLDF 6 hours after pneu mococcal challenge: 116.7 ± 17.4%). Pretreatment with BQ-123, a selective endothelin A receptor antagonist, had no sig nificant effect on ICP and brain water content, but augmented the increase in CBFLDF and CSF white blood cell count. Since
ET is known to trigger the release of nitric oxide (NO) by ET B receptor activation, we examined specific ET-NO interactions in primary rat cerebromicrovascular endothelial cells after stimulation with heat-killed pneumococci. Pneumococci in duced a significant increase in both ET and NO concentrations in endothelial cell culture medium. Treatment with phosphor amidon, an inhibitor of the endothelin-converting enzyme, pre vented the production of endothelin and markedly reduced NO generation. Our data provide evidence that ET is involved as a mediator in early pneumococcal meningitis in the rat and con tributes to the increase in CBFLDF, ICP, brain water content, and CSF pleocytosis, presumably through ET B receptor mediated NO production. Key Words: Pneumococcal menin gitis-Endothelin B receptor-Endothelin A receptor-Endo thelin-Nitric oxide-Endothelial cell culture-Rat. blood flow, ICP, brain water content, and the migration of leukocytes into the subarachnoid space (Pfister et aI., 1990; Weber et aI., 1996) . The molecular mechanisms underlying these changes involve both bacterial compo nents and host factors such as arachidonic acid metabo lites, cytokines, reactive oxygen species, and nitric oxide (NO), as well as leukocyte-endothelial interaction (Tuomanen et aI., 1989; Saukkonen et aI., 1990; Pfister et aI., 1990; Koedel et aI., 1995) .
Several arguments suggest that endothelin (ET) may be involved in the complex inflammatory network of early pneumococcal meningitis. In the cerebral vascula ture, intraluminal ET has been found to elicit vasodila tion through the induction of NO and prostanoids through an activation of the endothelin B (ET B) receptor (Kobari et aI., I 994a, b) . In addition, ET can cause an increase in blood-brain barrier permeability (Stan imirovic et aI., 1993) and plasma protein extravasation in rat dura mater (Bdindli et aI., 1996) . Besides its role as a regulator of the vascular tone and integrity, recent find ings strongly inQicate that ET is a mediator of inflam mation: bacterial cell wall components, inflammatory cy-tokines, and neutrophil-endothelial interactions can stimulate ET production (Ehrenreich et aI., 1990; Corder et aI., 1995) . Neutrophil lysosomal proteases can convert the propeptide big-ET into the mature ET. Moreover, ET interacts at the level of biosynthesis and biological ac tions with a variety of substances involved in the patho physiologic mechanisms of pneumococcal meningitis such as arachidonic acid metabolites, cytokines, and NO (Rubanyi and Polokoff, 1994) . A further sign that ET possibly plays a pathophysiologic role in meningitis is the occurrence of elevated ET levels in CSF samples of patients with bacterial meningitis that were obtained at the time of admission to the hospital (Koedel et aI., 1997) .
This study investigates the role of ET receptors in mediating pathophysiologic alterations during experi mental pneumococcal meningitis.
METHODS

Rat model of pneumococcal meningitis
A well-characterized rat model of bacterial meningitis was used in this study, which was previously described in detail (Pfister et al., 1990; Koedel et aI., 1995) . The protocols of this study were approved by the Government of Upper Bavaria. Thirty-two male Wistar rats (250 to 300 g) were anesthetized with 100 mg/kg thiopental (Byk Gulden, Konstanz, Germany) before undergoing tracheotomy, and then given artificial ven tilation with a small animal ventilator (AP-IO; K. Effenberger, Pfaffing, Germany). The MABP was measured through a can nula inserted into the right femoral artery using a pressure transducer (Statham P23, Viggo-Spectramed, Oxnard, CA, U.S.A.). Arterial blood samples were drawn at the beginning and the end of each experiment as well as every 2 hours and were analyzed for arterial Paco 2 , Pao 2 , and pH with a blood gas analyzer (IL 1304, Instrumentation Laboratory, Kirchheim, Germany). The right femoral vein was cannulated for fluid substitution and drug administration. Body temperature was monitored and maintained at 38.0° ± 0.5°C using a heating pad. The CSF samples were collected for white blood cell (WBC) count before and 6 hours after pneumococcal challenge. The ICP was recorded throughout the experiment with a pressure transducer (Statham P23, Viggo-Spectramed) connected to a cisterna magna catheter placed through a burr hole in the oc cipital bone (Pfister et aI., 1990) . For placement of the laser Doppler probe, a 5 x 4 mm area of the right parietal bone was gently abraded to a transparent bone layer while continuously rinsing with saline for cooling. The laser Doppler probe (model BPM 403a, vasamedics, St. Paul, MN, U.S.A.) held by a mi cromanipulator was placed over an area free of large dural and pial vessels according to the description of Weber et al (1996) . Cerebral blood flow, as measured continuously by laser Dopp ler flowmetry (CBFLDF), was expressed as percentage of a stable baseline of 100% (Pfister et aI., 1990) .
At the end of the experiment, rats were killed by exsangui nation, and brain water content, a parameter for brain edema formation, was determined as described previously (Pfister et aI., 1990) .
Induction of meningitis
When stable baselines of CBFLDF and ICP were achieved for 30 minutes, 100 �L CSF were removed through the cisterna magna catheter. Meningitis was induced by the intracisternal injection of 100 �L 108 colony forming units (cfu)/mL heat killed pneumococci (HKP). The preparation of pneumococci used in this study was previously described in detail (Koedel et aI., 1995) . Heat-killed (60°C for 4 hours), unencapsulated pneumococci stem from an isogenic mutant of the encapsulated strain S pneul11 0niae serotype 3 (no. 17260) (Koedel et aI., 1995) .
Experimental protocol of in vivo investigations
Rats were divided into the following experimental groups (seven total): group 1, untreated rats injected intracisternally with HKP (n = 8); group 2, rats injected intracisternally with HKP and pretreated with a selective ETB receptor antagonist, BQ-788 (n = 5) (Ishikawa et aI., 1994) ; group 3, rats injected intracisternally with HKP and treated with BQ-788 4 hours after intracisternal challenge (n = 4); group 4, rats injected intracisternally with HKP and pretreated with a selective en dothelin A (ET A ) receptor antagonist, BQ-123 (n = 7). To determine whether ET receptor antagonists by themselves can influence CBF LDF, ICP, brain water content, or CSF WBC count, we investigated the following control groups: group 5: untreated rats injected intracisternally with phosphate-buffered saline (PBS) (control; n = 3); group 6: control rats pretreated with BQ-788 (n = 3); and group 7: control rats pretreated with BQ-123 (n = 3). Both ET receptor antagonists were given intravenously in a dosage of 0.3 mg/kg as bolus injection, fol lowed by a continuous infusion of 0.3 mg/kg/h, similar to Ishi kawa and others (Ishikawa et aI., 1994) .
In vitro experiments
Recent studies provide evidence that the cerebral microvas cular endothelium plays a central role in the pathophysiologic mechanism of pneumococcal meningitis: namely, in the entry of bacteria into the CSF, the synthesis and release of inflam matory mediators, the adhesion and transmigration of leuko cytes, and the breakdown of the blood-brain barrier (Quagli arello et aI., 1986; Saukkonen et aI., 1990; Koedel et aI., 1995 . Tuomanen, 1996 . Cerebral microvascular endothelial cells can synthesize and release ET, and express both ET A and ET B receptors (Yoshimoto et aI., 1990; Nilsson et aI., 1997) . Stimu lation of ET B receptors in endothelial cells can induce the re lease of NO (Hirata et aI., 1993) . In recent studies, we showed that HKP can induce cerebral microvascular endothelial cells to produce NO, and that NO is a key mediator of early patho physiologic alterations in pneumococcal meningitis (Koedel et aI., 1995) . Thus, we tested whether HKP can stimulate cerebral microvascular endothelial cells to release ET, and whether the release of both ET and NO can be modulated either by NW_ nitro-L-arginine (L-NA), an NO synthase inhibitor, or by phos phoramidon, a metalloproteinase inhibitor capable of inhibiting the endothelin-converting enzyme.
Preparation of cerebromicrovascular endothelial cells
Endothelial cells from cerebral microvessels were isolated from 3-week-old Wistar rats as previously described (Koedel et aI., 1995) . Cortical tissue was cleaned of meninges and super ficial vessels with fine forceps under a binocular microscope. The hemispheres were incubated with 0.75% collagenase for 1 hour at 37°C, After centrifugation with 25% bovine serum albumin for 20 minutes at 800 x g, the cell suspension was incubated with 0.1 % collagenase/dispase (Boehringer Mann heim, Germany) for 30 minutes at 37°C. After centrifugation, the pellet was fractionated with a 33.3% Percoll gradient. The cell layer of the gradient was plated in Dulbecco's modified Eagle's medium (Biochrom, Berlin, Germany) and then supple mented with 20% fetal calf serum (Biochrom) and 25 j-Lg/mL endothelial cell growth factor (Boehringer Mannheim). After 3 to 5 days, the endothelial cells formed a confluent monolayer (approximately 5 x 105 cells/well). All monolayers were char acterized as endothelial cells by morphologic criteria and the ability to bind antibody to von Wille brand factor (Boehringer Mannheim). For the experiments, monolayers without any pas sage were washed with PBS without Ca 2 + or Mg 2 + and main tained in Dulbecco's modified Eagle's medium with 20% fetal calf serum and 20 j-Lg/mL endothelial cell growth factor without antibiotics and phenol red.
Experimental groups of in vitro experiments
The following three groups were investigated'. endothelial cells stimulated with 107 cfu/mL HKP that were 1) untreated (n = 8), 2) treated with L-NA (1 mmollL; n = 6), or 3) treated with phosphoramidon (100 j-LmoIlL; n = 6). Endothelial cells cultured in the absence of HKP (n = 6) were negative controls, and endothelial cells stimulated with thrombin (10 U/mL; n = 6), a known inducer of ET release, were positive controls. Both ET and nitrite concentrations in the cell culture medium were measured 48 hours after stimulation. To investigate whether HKP influenced ET concentrations, ET levels were determined in the cell culture medium in the absence of endothelial cells after incubation with 107 cfu/mL HKP (n = 4) and compared with cell culture medium alone (n = 4).
Determination of nitrite and endothelin concentrations in the cell culture medium
The NO production was assessed by measuring nitrite, a stable metabolic product of NO, using the Griess reaction (Koe del et aI., 1995). The ET concentrations in cell culture medium were measured by a radioimmunoassay as described previously (Arendt et aI., 1993) . For determining nitrite and ET, detection limits of 0.2 j-LmollL and 1 pmol/L, respectively, were found for the test samples.
Reagents
We used BQ-123, a selective ET A antagonist, and BQ-788, a selective ETB antagonist from Alexis (Grunberg, Germany), as well as the metalloproteinase inhibitor phosphoramidon and the nitric oxide synthase inhibitor L-NA from Sigma Chemicals (Deisenhofen, Germany).
Statistical analysis
For statistical analysis, data on CBFLDF and rcp obtained 3 hours and 6 hours after intracisternal pneumococcal challenge were compared by one-way analysis of variance and Scheffe's test. P values were corrected for repeated measures using the Bonferroni-Holm procedure. One-way analysis of variance and Scheffe's test were applied for statistical analysis of data on brain water content, CSF WBC count, and concentrations of ET and NO/nitrite in cell culture medium. To detect changes over time within the control group (group 5) in the in vivo experi ments, data were compared using repeated measures analysis of variance. A P value < 0.05 was considered significant. Data are given as mean ± SO.
RESULTS
In vivo experiments
Mean arterial blood pressure, Pa02> Paco2, pH, and hematocrit were within normal ranges throughout the experiment (Table 1) . Small differences between groups were not statistically significant.
In untreated rats injected intracisternally with PBS (control rats), there was no significant change in CBFLDP or ICP throughout the experiment, and they did not de velop CSF pleocytosis. Brain water content measured in control rats was 77. 41 ± 0.16%. In rats injected intracis ternally with PBS, systemic administration of neither BQ-788 nor BQ-123 led to changes in CBFLDP' ICP, brain water content, or CSF WBC count (P > 0.05, com pared with untreated control rats; Table 2 ).
Challenge with HKP induced a significant increase in CBFLD P ' ICP, brain water content, and CSF WBC count Table 2 ). Pretreatment with BQ-788 significantly attenuated these pathophysiologic alterations ( Fig. 1 ; Table 2 ). In contrast, pretreatment with BQ-123 failed to prevent the increase of ICP and brain water content seen after injection with HKP. Moreover, when injecting BQ-123, a significant increase in CBFLDF and CSF pleocy tosis was observed ( Table 1) .
Administration of BQ-788 4 hours after intracisternal challenge did not reverse the increase in CBFLDP (6 hours after pneumococcal challenge: 196.1 ± 25. 8%, compared with 225.3 ± 2l. 8% in untreated rats injected intracisternally with HKP; not significant) and rcp, and had no effect on brain edema formation and CSF pleo cytosis (Table 2 ).
In vitro experiments
Nitrite concentrations in the cell culture supernatant of unstimulated endothelial cells (medium control) were be low the detection limit. Stimulation with HKP induced a marked increase in nitrite levels (7.2 ± l.8 j.LmollL; P < 0.05 compared with medium control). Administration of L-NA prevented the increase in nitrite concentrations (0.9 ± 0.3 j.Lmol/L; P < 0.05 compared with untreated endo thelial cells stimulated with HKP). Treatment with phos phoramidon significantly reduced NO release by endo thelial cells (2.7 ± 0.9 j.LmollL; P < 0.05 compared with both medium control and untreated endothelial cells stimulated with HKP).
The ET concentration in cell culture supernatants of unstimulated endothelial cells (negative control) was 5.5 ± 2.4 pmol/L, suggesting a constitutive ET release. This result was supported by previous observations of immu noreactive ET -1 in the supernatants of bovine and rat micro vessel endothelial cells in short-term culture (Du rieu-Trautmann et al., 1993; Yoshimoto et al., 1990) . Stimulation with thrombin, a known inducer of ET se cretion, caused a pronounced elevation of immunoreac tive ET-l in the cell culture medium (49.7 ± 23.6 pmol/ L; P < 0.05 compared with negative control). Heat-killed pneumococci induced a significant increase in immuno reactive ET-l (17.8 ± 2.7 pmol/L; P < 0.05 compared with negative control). No increase in immunoreactive ET -1 concentrations was detected when HKP were incu bated in medium in the absence of endothelial cells. Treatment with phosphoramidon but not with L-NA sig nificantly attenuated ET release on stimulation with HKP (7.9 ± 6.2 pmol/L and 13.3 ± 1.9 pmol/L, respectively).
DISCUSSION
The major finding of this study was that the ET B re ceptor antagonist BQ-788 significantly attenuated the in crease in CBF LDF , ICP, brain water content, and CSF WBC count in early pneumococcal meningitis. There are three possible reasons for the failure of BQ-788 to com pletely inhibit pathophysiologic changes in our study: 1) involvement of other mediators than ET, 2) restricted access of peptidergic antagonists such as BQ-788 to the brain and, thus, to abluminal ET B receptors, or 3) addi tional ET receptor subtypes, which cannot be blocked by BQ-788 .
To date at least two distinct types of ET receptors have been described: ETA and ET B receptors. The ETA recep tor has a higher affinity for ET-1 and ET-2 than for ET-3, J Cereh Blood Flow Metab. Vol. 18, No. I, 1998
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7. 42 ± 0. 02 7. 40 ± 0. 02 47 ± 1 46 ± 1 and the ET B is nonselective for all three ET isopeptides (Sokolovsky, 1995) . Pharmacologic data also support the existence of more than these two conventional receptor SUbtypes. For example, Wren and coworkers (1993) showed that whereas ET-3 can mediate cell proliferation in wounded human umbilical vein endothelial cells, nei ther ET-1 nor ET-2 can. This response cannot be medi ated by the currently defined ETA and ET B receptors. In accordance with Wren and colleagues (1993), a third ET receptor SUbtype, which preferentially binds ET-3, was suggested to be expressed on bovine endothelial cells (Emori et aI., 1990) , rabbit vascular smooth muscle cells (Douglas et aI., 1995) , and in rat cerebellar homogenates (Widdowson and Kirk, 1996) . This receptor SUbtype might be related to the ETc receptor subtype, which was cloned from Xenopus laevis dermal melanophores (Kame et aI., 1993) . Since binding and functional data pointing to the existence of a third ET receptor subtype are scarce, and a mammalian homologue of this receptor has not yet been identified, it remains unclear whether the failure of BQ-788 to completely inhibit pathophysi ologic changes in our study is related to the ETc recep tor. The presence of receptors for ET in rat and human brain has been demonstrated in autoradiographic binding and in situ hybridization studies, Specific ET -binding sites were observed in neurons, astrocytes, microglial cells, vascular smooth muscle cells, and cerebromicro vascular endothelial cells (Rubanyi and Polokoff, 1994; Sokolovsky, 1995) . The mammalian brain predomi nantly contains the ET B receptor subtype (Fernandez Durango et aL, 1994) . The ETB receptor is believed to exist mainly on endothelial, neuronal, and glial cells (Harland et aL, 1995; Lysko et aL, 1995; Nilsson et aL, 1997) . The ETA receptor is mainly expressed by vascular smooth muscle cells, but it is also abundant on endothe lial, neuronal, and glial cells but to a far less degree (Vigne et al., 1990; Lysko et al., 1995; Nilsson et al., 1997) . Studies report that ET -1 failed to cross the normal blood-brain barrier (Koseki et a1., 1989) . Similarly to ET, its peptidergic receptor antagonists, such as BQ-123 and BQ-788, presumably are unable to pass through the blood-brain barrier (Clozel and Watanabe, 1993) . In our experiments, we found that BQ-788 had an effect when given by the intravenous route. The effect of BQ-788, as observed in our study, indicates that the agent is able to gain access to ET B receptors mediating pathophysiologic alterations in pneumococcal meningitis. The most prob able explanation is that ET B receptors are located in the intravascular compartment, namely on cerebromicrovas cular endothelial cells. Since the permeability of the blood-brain barrier is compromised during pneumococ cal meningitis (Quagliarello et aL, 1986) , it is also con- ceivable that BQ-788 may gain direct access to ablumi nal ET B receptors on glial and neuronal cells.
Another important finding of this study was that sys temic administration of the ETA receptor antagonist BQ-123 significantly augmented the increase in CBFLDF and CSF WBC count. Our data on the efficacy of intravenous BQ-123 contradict most of the available information about the site of BQ-123 action in the brain. For ex ample, Clozel and Watanabe (1993) demonstrated that BQ-123 prevented early cerebral vasospasm that follows subarachnoid hemorrhage after intracisternal but not in travenous injection. However, the observation of the ef fectiveness of intravenously administered BQ-123 in preventing cerebral postischemic hypoperfusion in ger bils agrees with our findings (Spatz et a1., 1996) . More over, Kobari et a1. (l994a) describe a decline in cerebral blood volume after intracarotid administration of a low dose of ET-l; this was prevented with BQ-123 given by the same route. These authors suggest that BQ-123 may act on vasoconstrictive ET receptors located in the cere brovascular endothelium.
Functional studies have pointed to a variety of bio chemical effects elicited by activation of ETA and ET B receptors in the mammalian brain. Originally ET was described to be a highly potent vasoconstrictor (Yanag isawa et a1., 19 88). Although ET (i.e., ET-1) consistently has potent constriGtive effects on isolated cerebral ves sels in vitro (Salom et a1., 1995) , findings on the action of exogenous ET on the cerebral circulation in vivo vary. When applied from the abluminal side, ET-l induced a pronounced constriction of cerebral arteries and a de crease in cerebral perfusion, which could be prevented by selective ETA receptor antagonists (Rubanyi and Polokoff, 1994; Salom et aI., 1995) . Low doses of ablu minal ET -1, however, occasionally may dilate pial arter ies' probably through the induction of prostanoids and NO (Armstead et aI., 1989) . In addition, topical applica tion of the ETB receptor agonists IRL-1620 and BQ-3020 was shown to mediate dilation of rat basilar artery and feline cerebral resistance arterioles, which were depen dent on NO production (Kitazono et aI., 1995; Patel et aI., 1996) . Vol. 18, No. 1, 1998 When ET was given intravascularly, ET was reported to have diverse effects on cerebral vessels: some ob served a vasodilatory effect, whereas others reported ei ther no or even a vasoconstrictive effect. Intraarterial infusion of ET-l and BQ-3020 caused no change in di ameters of canine major cerebral arteries or feline cere bral resistance arterioles, respectively (Shigeno et aI., 1989; Patel et aI., 1996) . Even a decrease in cerebral perfusion was demonstrated after direct injection of ET-l into the cerebral circulation of the goat (Salom et aI., 1991) . In contrast, an increase in cerebral perfusion was found after intracarotid infusion of high doses of either ET-l or IRL-1620 in cats (Kobari et aI., 1994a (Kobari et aI., , 1994b . Similarly, Willette and others (1990) report increased cortical microvascular perfusion in rats either after intra carotid or intravenous administration of ET -1, and Weitzberg and associates (1993) describe cerebral vaso dilation after intravenous infusion of ET -1 in humans. These discrepancies may depend on differences in vas cular beds and species investigated in the aforemen tioned studies.
Since ET is constitutively produced by cerebrovascu lar endothelial cells, as observed in our and previous studies (Yoshimoto et aI., 1990; Durieu-Trautmann et aI., 1993) , a basal ET-mediated cerebrovascular tone may be present. However, our observation that neither BQ-788 nor BQ-123 modulated CBF LDF when administered in control rats contradicts this hypothesis, but agrees with a variety of recently published studies demonstrating that ET receptor antagonists have no effect on diameters of cerebral vessels or cerebral perfusion under physiologic conditions (Clozel and Watanabe, 1993; Kobari et aI., 1994a) .
The ET and ET receptor SUbtypes may play a major role in the pathophysiologic mechanisms of CNS dis eases, namely, as a mediator of vasoconstriction and re duced cerebral perfusion. Three reasons support this sug gestion: 1) far greater amounts of ET-J have been de tected in the CSF of patients with a variety of neurologic disorders such as cerebral ischemia and subarachnoid hemorrhage than in normal human CSF; 2) the expres sion of ET receptors was increased in the aforementioned diseases; and 3) inhibitors of ET production and selective ET receptor antagonists showed beneficial effects on the respective disease in animal models of the disease (Ru banyi and Polokoff, 1994; Salom et aI., 1995) .
In the current study, we report that BQ-788 attenuated the increase in CBF L D F and CSF WBC count, whereas BQ-123 augmented these pathophysiologic alterations. There are several possible explanations for our observa tion. First, as mentioned earlier, the vasomotor effect of ET probably is composed of relaxant and contractile components that compete with each other. Blockade of ETA receptors, which. mainly mediate the vasoconstric tive effects of ET, may thus lead to some potentiation of ET-induced vasodilation and, therefore, to an enhanced increase in cerebral perfusion, as we observed. Second, ETA blockade may be accompanied by a greater access of ET to ET B receptors, thus amplifying ET B receptor mediated biochemical effects. Through ET B receptor ac tivation, ET was shown to stimulate its own production in rat aortic endothelial cells and in human umbilical endothelial cells (Fujitani et aI., 1992; Saito et aI., 1995) , the synthesis of NO by bovine endothelial cells (Hirata et al., 1993) , cytokine production by human umbilical en dothelial cells (Stankova et aI., 1996) , prostacyclin re lease in guinea pig aortic rings (Matsuda et aI., 1993) , the expression of adhesion molecules on rat aortic endothe lial cells (Hayasaki et aI., 1996) , and the enhancement of human neutrophil chemotaxis (Elferink and de Koster, 1996) . In addition, ET -induced increases of either cere bral perfusion or diameters of cerebral vessels in cats and rats (Willette et aI., 1990; Kobari et aI., 1994a Kobari et aI., , 1994b , as well as an increase of the vascular permeability in the rat dura mater (Bdindli et aI., 1996) , have been reported to be mediated by ET B receptor activation. All of these biochemical and pathophysiologic mechanisms have been implicated in the pathophysiologic mechanism of pneumococcal meningitis. Thus, an amplification of these mechanisms may contribute to the observed aug mentation of the increase in CBF LDF and WBC counts after BQ-123 administration.
During the last several years, experimental studies have shown that the pathophysiologic mechanisms of pneumococcal meningitis are complex. Animal studies have provided evidence that cytokines (Saukkonen et aI., 1990) , arachidonic acid metabolites (Pfister et aI., 1990) , neuropeptides (Weber et aI., 1996) , reactive oxygen spe cies (Pfister et aI., 1990) , NO (Koedel et aI., 1995) , and leukocyte-endothelial interaction (Tuomanen et aI., 1989) are involved in the pathophysiologic mechanisms. Several reports indicate that ET may interact with these mediators: ET can stimulate the release of cytokines (Stankova et aI., 1996) , arachidonic acid metabolites (Matsuda et al., 1993) , neuropeptides (Ritz et aI., 1992) , and NO (Hirata et aI., 1993) . Also, ET can up-regulate the expression of adhesion molecules including ICAM-1, VCAM-l, and E-selectin (McCarron et aI., 1993; Hay asaki et aI., 1996) and can induce neutrophil adhesion to endothelial cells (Hayasaki et aI., 1996) . Furthermore, ET can exert chemoattractant activity for neutrophils (Elferink and de Koster, 1996) and can modulate phago cyte function, such as potentiating fMet-Leu-Phe activated superoxide production (Ishida et aI., 1990) .
In this study, cerebrornicrovascular endothelial cells were induced to release both NO and ET on stimulation with pneumococci. Inhibition of the endothelin converting enzyme with phosphoramidon prevented the increase in ET concentrations and markedly reduced NO release. These data help elucidate one possible mode of action of the ET B receptor antagonist: BQ-788 inhibits ET -binding to ET B receptors, thus reducing the genera tion of NO, which has been identified as a central me diator of pneumococcal meningitis (Koedel et aI., 1995) . The role of ET in the pathophysiologic mechanism of pneumococcal meningitis was supported by our previ ously published observation that elevated ET levels can be detected in CSF samples of patients with bacterial meningitis obtained on admission to the hospital (Koedel et aI., 1997) .
In conclusion, our data indicate that ET is a mediator in early pneumococcal meningitis in the rat and contrib utes to the increase in CBF LDF , ICP, brain water content, and CSF pleocytosis, presumably by ETB receptor mediated NO production.
